Amneal Pharmaceuticals Inc. (AMRX)
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?
The consensus price target hints at a 34.8% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amneal 2026-2027 Upside From Biosimilars Scale
AMRX targets 2027 upside through biosimilars scale, new complex launches, and Specialty recovery after 2026 Rytary erosion pressure.
AMRX Growth Drivers: Generics, Biosimilars, and Crexont
Amneal leans on generics stability, biosimilar launches, and Crexont growth as 2026 guidance points to higher EBITDA and EPS despite Specialty headwinds.
AMRX Valuation: What 1.69x Sales Means for Investors
Amneal trades at 1.69x sales, below sector benchmarks, as investors weigh raised 2026 profit guidance against Specialty pressure and launch execution.
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMRX Announces Kashiv BioSciences Buyout, Solid Q1 Preliminary Results
Amneal's deal to buy Kashiv for up to $1.10B aids biosimilar push. The company posts strong preliminary Q1 results and raises 2026 EPS guidance.
